Table 2.

Clinicopathological characteristics of 312 endometrial cancers according to DNA mismatch repair (MMR) protein status.

		MMR deficient	MMR proficient	p
n		116	196
age	Median (95%CI)	63.2 (60.1–64.8)	63.1 (61.9–63.8)	0.98
Family history of cancer	Yes	38 (34.2%)	46 (25.5%)	0.26
	No	73 (65.8%)	134 (74.4%)
Body Mass Index	Median (95%CI)	31.1 (29.4–32.4)	30.4 (29.7–31.6)	0.33
Histological type	Endometrioid	102 (87.9%)	148 (75.5%)	0.008
	Non-endometrioid	14 (12.1%)	48 (24.5%)
FIGO	I/II	81 (69.8%)	139 (70.9%)	0,84
	III/IV	35 (30.2%)	57 (29.1%)
ESMO-ESGO-ESTRO	low	38 (32.8%)	59 (30.1%)	0.020
	intermediate	5 (4.3%)	29 (14.8%)
	High-intermediate	15 (12.9%)	12 (6.1%)
	High	54 (46.6%)	91 (46.4%)
	Advanced/metastatic	4 (3.4%)	5 (2.6%)
Grade	Low	85 (73.3%)	137 (69.9%)	0,52
	High	31 (26.7%)	59 (30.1%)
Tumor size (cm)	Mean (95% CI)	4 (3.7–4.5)	4 (3.7–4.5)	0.84
Tumor size	≤2.0 cm	13 (12.4%)	27 (15.3%)	0,50
	>2.0 cm	92 (87.6%)	150 (84.7%)
	NA	11	19
Myometrial invasion	<50%	61 (52.6%)	109 (55.9%)	0,57
	≥50%	55 (47.4%)	86 44.1%)
	NA		1
LVSI	No/focal	84 (72.4%)	162 (83.1%)	0.025
	Multifocal	32 (27.6%)	33 (16.9%)
	NA		1
MELF	Absent	89 (76,7%)	132 (67.7%)	0.090
	Present	27 (23.3%)	63 (32.3%)
	NA	0	1
Node	Negative	88 (77.2%)	154 (61.8%)	0,78
	Positive	26 (22.8%)	42 (21.4%)
	NA	2	0
Recurrence		8/115 (6.9%)	29/195 (14.8%)	0.02***
Death of disease		9/110 (8.2%)	22/192 (11.5%)	0.31***
Any unfavorable event (recurrence and/or death associated with disease)		11/106 (10.38%)	32/185 (17.5%)	0.07***

LVSI: lymphovascular space invasion; MELF: microcystic, elongated, and fragmented; NA: not avaible.

*Mann-Whitney test; ** Chi-square test; *** logrank test.